271 related articles for article (PubMed ID: 37569269)
1. An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective.
Cordani N; Bianchi T; Ammoni LC; Cortinovis DL; Cazzaniga ME; Lissoni AA; Landoni F; Canova S
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569269
[TBL] [Abstract][Full Text] [Related]
2. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
3. Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
Gomez MK; Illuzzi G; Colomer C; Churchman M; Hollis RL; O'Connor MJ; Gourley C; Leo E; Melton DW
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526907
[TBL] [Abstract][Full Text] [Related]
4. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
Revythis A; Limbu A; Mikropoulos C; Ghose A; Sanchez E; Sheriff M; Boussios S
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886427
[TBL] [Abstract][Full Text] [Related]
5. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
Boussios S; Karihtala P; Moschetta M; Abson C; Karathanasi A; Zakynthinakis-Kyriakou N; Ryan JE; Sheriff M; Rassy E; Pavlidis N
Invest New Drugs; 2020 Feb; 38(1):181-193. PubMed ID: 31650446
[TBL] [Abstract][Full Text] [Related]
6. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
7. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
8. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
[TBL] [Abstract][Full Text] [Related]
9. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
10. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
[TBL] [Abstract][Full Text] [Related]
11. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
Gadducci A; Guerrieri ME
Crit Rev Oncol Hematol; 2017 Jun; 114():153-165. PubMed ID: 28477743
[TBL] [Abstract][Full Text] [Related]
13. [Molecular Mechanisms of Carcinogenesis of Epithelial Ovarian Cancers].
Müllerová Z; Müller T; Křivánková K; Vojtěšek B; Müller P
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):46-53. PubMed ID: 27846720
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas.
Milanesio MC; Giordano S; Valabrega G
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455819
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA; Tinker AV
BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
[TBL] [Abstract][Full Text] [Related]
16. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
17. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer.
Giannini A; Di Dio C; Di Donato V; D'oria O; Salerno MG; Capalbo G; Cuccu I; Perniola G; Muzii L; Bogani G
Am J Clin Oncol; 2023 Sep; 46(9):414-419. PubMed ID: 37314974
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
20. Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
Xie T; Dickson KA; Yee C; Ma Y; Ford CE; Bowden NA; Marsh DJ
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
